Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

4-HPR modulates gene expression in ovarian cells.

Molly Brewer1, Nathaniel D Kirkpatrick, J Taylor Wharton

  • 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Arizona Cancer Center, Tucson, 85724, USA.

International Journal of Cancer
|March 30, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controversies in the organization and structure of management for rare tumors.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024
Same author

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024
Same author

Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2023
Same author

Novel therapeutics in low-grade serous ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2023
Same author

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.

Gynecologic oncology·2022

The retinoid 4-(N-hydroxyphenyl) retinamide (4-HPR) shows promise for ovarian cancer, acting preventively in premalignant cells and therapeutically in cancer cells by altering gene expression and cell metabolism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer frequently recurs post-chemotherapy, necessitating novel therapeutic and chemopreventive strategies.
  • Retinoids, particularly 4-(N-hydroxyphenyl) retinamide (4-HPR), are emerging as potential agents in ovarian cancer management.
  • Understanding the precise mechanisms of 4-HPR action is crucial for optimizing its clinical application.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying the activity of 4-HPR in both premalignant ovarian surface epithelial (IOSE) cells and ovarian cancer (OVCA433) cells.
  • To investigate the differential effects of 4-HPR on gene expression, cellular metabolism, and redox status in distinct ovarian cell types.
  • To assess the potential of 4-HPR as both a chemopreventive and therapeutic agent for ovarian cancer.

Related Experiment Videos

Main Methods:

  • DNA microarray analysis to assess global gene expression changes induced by 4-HPR.
  • Quantitative real-time RT-PCR and Western blotting to validate microarray findings.
  • Optical fluorescence spectroscopy to examine metabolic alterations and redox status.

Main Results:

  • 4-HPR upregulated proapoptotic genes and mitochondrial uncoupling protein in OVCA433 cells, indicating a pro-death effect.
  • 4-HPR modulated RXR receptors in IOSE cells, suggesting a role in cellular differentiation or prevention.
  • Downregulation of mutant BRCA genes was observed in both cell types, potentially enhancing therapeutic efficacy.
  • Differential impact of 4-HPR on cellular redox balance was noted between IOSE and OVCA433 cells.

Conclusions:

  • 4-HPR exhibits distinct mechanisms of action in premalignant versus cancerous ovarian cells.
  • The compound demonstrates potential as a chemopreventive agent for ovarian surface epithelium.
  • 4-HPR shows therapeutic promise in ovarian cancer treatment by inducing apoptosis and modulating key cellular pathways.